Table 2 Drugs associated with mitophagy modulators
From: The mitophagy pathway and its implications in human diseases
Pharmaceutical | Targeted pathway | Diseases | Physiological functions and disease links | References |
|---|---|---|---|---|
Urolithin A | Promote mitophagy | Parkinson’s disease | Inhibit NLRP3 inflammasome activation via promoting mitophagy, protecting against dopaminergic neurodegeneration and neuroinflammation | |
6′′′-Feruloylspinosin | Promote the expression of PINK1/Parkin | Alzheimer’s disease | Alleviate beta-amyloid induced toxicity by promoting mitophagy | |
UMI-77 | Activate PINK1 signaling | Alzheimer’s disease | Ameliorate cognitive decline and amyloid pathologies | |
Kaempferol, Rhapontigenin | Activate mitophagy | Alzheimer’s disease | Increased the survival and functionality of glutamatergic and cholinergic neurons, abrogated amyloid-β and tau pathologies, and improved the animals’ memory | |
Spermidine | Promote the expression of PINK1-PDR1 | Neurodegenerative diseases | Ameliorate the symptoms of neurodegenerative and premature aging diseases by promoting PINK1-PDR1-dependent mitophagy pathway | |
Baicalein | Activate FUNDC1 signaling | Cardiac hypertrophy | Attenuate cardiac hypertrophy via suppressing oxidative stress and activating mitophagy | |
α-lipoic acid | Activate FUNDC1 signaling | Heart failure | Protect against pressure overload-induced heart failure via FUNDC1 dependent mitophagy signaling | |
Ellagic acid | Suppress BNIP3 overexpression | Heart failure | Suppress BNIP3 induced mitochondrial injury and cell death in ventricular myocytes | |
Resveratrol | Upregulate the mitochondrial translocation of Parkin | Myocardium aging | Alleviate Senescent-Like Cell Phenotypes by promoting Parkin-mediated mitophagy | |
Tetrahydroberberrubine | Promote PHB2 overexpression | Myocardium aging | Promote mitophagy and retard cardiomyocyte senescence | |
Oxyberberine, MCTR3 | Downregulate PINK1/Parkin signaling | Acute lung injury | Alleviate LPS-induced inflammation in ALI via inhibition of mitophagy | |
Bone morphogenetic protein 4 | Activate PINK1 signaling | Idiopathic pulmonary fibrosis | BMP4 attenuates fibroblast-to-myofibroblast differentiation by reducing impaired mitophagy and cellular senescence in lung fibroblasts | |
Quercetin | Promote the expression of SIRT1/PINK1 | Kidney fibrosis | Alleviate kidney fibrosis through the SIRT1/PINK1/mitophagy axis | |
Tetramethylpyrazine | Promote the expression of PINK1/Parkin | Alcoholic liver disease | Contribute to necroptosis inhibition by facilitating PINK1/parkin-mediated mitophagy | |
Cyanidin-3-O-glucoside, Quercetin | Promote the expression of PINK1/Parkin | Non-alcoholic fatty liver disease | Alleviate hepatic steatosis by enhancing PINK1/Parkin-dependent mitophagy | |
Akebia Saponin D | Promote the expression of BNIP3 | Non-alcoholic fatty liver disease | Alleviate hepatic steatosis by promoting BNIP3 induced mitophagy | |
Zinc oxide nanoparticles | Promote the expression of PINK1/Parkin | Tongue squamous cell carcinoma | Induce toxicity in CAL 27 oral cancer cell lines by activating PINK1/Parkin-mediated mitophagy | |
Aloe gel glucomannan | Promote the expression of PINK1/Parkin | Colon cancer cells | Induce cytotoxic mitophagy through ROS-related PINK1/Parkin pathway | |
Ketoconazole | Downregulate cyclooxygenase-2, accumulation PINK1/Parkin | Hepatocellular carcinoma (HCC) | Exacerbate mitophagy to induce apoptosis, thereby inhibiting the growth of HCC | |
Flavaglines compound 3 | Inhibit PHB2-PARL-PGAM5-PINK1 axis | Cancer | Inhibit PHB2-mediated mitophagy and effectively block cancer cell growth | |
Qidan Tiaozhi capsule | Activate AMPK/PINK1-Parkin-mediated mitophagy | Metabolic syndrome | Suppress oxidative stress to treat metabolic syndrome |
